Our drug discovery platform is focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases including acute lung injury, Acute Respiratory Distress Syndrome, Bronchopulmonary Dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia.
Our lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks a key upstream priming signal involved in the aberrant activation of the NLRP3 inflammatory cascade.
Initial indications target severe inflammatory pulmonary diseases with significant unmet needs.
For many inflammatory and fibrotic lung diseases, no effective preventative or therapeutic treatments exist. With limited options for disease management, these severe and acute lung conditions exert a considerable burden on patients, families, and healthcare providers, including higher rates of mortality, longer lengths of stay in intensive care units, and life-long morbidities.
A serious lung disorder that occurs in response to various causes such as pneumonia, sepsis, or trauma, ARDS can lead to inflammation and lung damage resulting in severe respiratory failure.
Often unpredictable, acute exacerbations of this chronic lung disease worsen lung function, leading to significant morbidity and earlier mortality.
Affecting premature infants who require mechanical ventilation and oxygen therapy and characterized by abnormal development and lung inflammation, BPD can lead to chronic pulmonary problems.
SARS-CoV-2 and influenza A-related pneumonia can lead to severe respiratory distress, acute respiratory distress syndrome (ARDS), and death.
